Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 6—June 2023
Synopsis

Association of Persistent Symptoms after Lyme Neuroborreliosis and Increased Levels of Interferon-α in Blood

Sergio A. Hernández, Katarina Ogrinc, Miša Korva, Andrej Kastrin, Petra Bogovič, Tereza Rojko, Keith W. Kelley, Janis J. Weis, Franc Strle, and Klemen StrleComments to Author 
Author affiliations: Tufts University School of Medicine, Boston, Massachusetts, USA (S.A. Hernández, K. Strle); New York State Department of Health, Albany, New York, USA (S.A. Hernández, K. Strle); University Medical Center Ljubljana, Ljubljana, Slovenia (K. Ogrinc, P. Bogovič, T. Rojko, F. Strle}; University of Ljubljana, Ljubljana (M. Korva, A. Kastrin); University of Illinois, Urbana-Champaign, Illinois, USA (K.W. Kelley); University of Utah, Salt Lake City, Utah, USA (J.J. Weis)

Main Article

Figure 3

Cytokine and chemokine levels in serum of patients in Slovenia who had Lyme neuroborreliosis in study of association of persistent symptoms after Lyme neuroborreliosis and increased levels of interferon-α in blood. Prevalence of constitutional symptoms is stratified according to PTLDS severity during the 1-year follow-up period. A) Median serum levels of IFN-α, IL-23, and CCL19 during 1 year of follow-up stratified by presence or absence of PTLDS. B) Median serum levels of IFN-α, IL-23, and CCL19 graphed according to disease severity. p values above red line correspond to the comparison between patients with severe PTLDS vs those with no PTLDS (resolved). p values above yellow lines represent significant differences between the no PTLDS and moderate PTLDS groups. C) Analysis of variance comparison of relative effect of disease severity or time on cytokine levels in serum. Error bars indicate 10th–90th percentiles CIs. CCL, CC motif chemokine ligand; IFN, interferon; IL, interleukin; PTLDS, posttreatment Lyme disease symptoms or syndrome.

Figure 3. Cytokine and chemokine levels in serum of patients in Slovenia who had Lyme neuroborreliosis in study of association of persistent symptoms after Lyme neuroborreliosis and increased levels of interferon-α in blood. Prevalence of constitutional symptoms is stratified according to PTLDS severity during the 1-year follow-up period. A) Median serum levels of IFN-α, IL-23, and CCL19 during 1 year of follow-up stratified by presence or absence of PTLDS. B) Median serum levels of IFN-α, IL-23, and CCL19 graphed according to disease severity. p values above red line correspond to the comparison between patients with severe PTLDS vs those with no PTLDS (resolved). p values above yellow lines represent significant differences between the no PTLDS and moderate PTLDS groups. C) Analysis of variance comparison of relative effect of disease severity or time on cytokine levels in serum. Error bars indicate 10th–90th percentiles CIs. CCL, CC motif chemokine ligand; IFN, interferon; IL, interleukin; PTLDS, posttreatment Lyme disease symptoms or syndrome.

Main Article

Page created: March 23, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external